Sepsis hospitalization was higher in the presence of most risk factors, with greater effects in women with a history of chronic obstructive pulmonary disease, dyslipidemia, myocardial infarction and smoking, compared with men.
Latest Articles
ABL/PI5P enhances anti-Mycobacterium abscessus response of macrophages from people with CF, receiving or not ETI therapy. Our results support the possible development of ABL/PI5P treatment as host-directed therapy against M. abscessus infection, especially in people with CF who cannot access ETI treatment.
Viewpoint Articles
As pathogen molecular diagnostics technology develops, the software analysis of polymerase chain reaction sigmoidal curves, cycle threshold (Ct) values, and the limit of nucleic acid detection for that assay is not always available when reporting test results. These are critical components in ...
Measles cases are increasing globally and in the United States because of low routine measles vaccine coverage and disruptions to immunization services during the coronavirus disease 2019 (COVID-19) pandemic. To achieve and sustain measles elimination requires maintaining high coverage with 2 doses of measles vaccine, addressing vaccine hesitancy and misinformation, strong political commitment, and the necessary financial resources.
Causal inference is a branch of statistics that attempts to quantify the impact of a treatment or intervention on an outcome, recognizing that, when experimentation is impossible, the treatment allocation may not be independent of other factors that predict the outcome. Rather, there may be common ...
The first demonstration of the importance of iDNA as a source of HBsAg is a tour-de-force study by Wooddell et al [ 11 ] who showed that a small interfering RNA (siRNA) administered to persons with HBeAg-positive CHB led to nearly 100-fold decreases in HBsAg levels. In contrast, persons with ...
New article series on TB Isolation
Clinical Infectious Diseases (CID) and The Journal of Infectious Diseases (JID) have partnered to publish a new article series on TB Isolation. This series, developed in response to the new guidelines from National Tuberculosis Coalition of America, offers essential perspectives for clinicians, researchers, and public health professionals.
Read now
Vaccine Sciences Article Series
Explore a new article series on vaccine sciences, led by Dr. Helen Chu, featuring a wide range of topics including global health and access, systems vaccinology, and vaccine hesitancy. Beginning in December 2024 and continuing throughout 2025, each JID issue highlights perspectives from leading experts, advancements over the past decade, and future opportunities.
Read now
JID is now on Bluesky!
We are excited to announce that The Journal of Infectious Diseases now has an official presence on Bluesky! Follow us for the latest updates, research highlights, and more to stay connected with cutting-edge developments in infectious diseases.
Find us at @jidjournal.bsky.social
JID Now Offers Review Pathway for Papers Rejected by High-Impact Journals
The Journal of Infectious Diseases welcomes papers that have been peer reviewed by another medical journal and were not accepted for publication, where the authors believe they can address the essential concerns identified by previous reviewers. Under this new pathway, authors can revise the paper according to the review comments they previously received and then submit the paper to JID. This new pathway is intended to speed publication and minimize unnecessary re-review of papers that previously received thorough and detailed review elsewhere.
Learn more about how to submit using this pathway.
Latest Supplements
Explore the latest supplements from JID:
Advancing Respiratory Virus Surveillance and Preparedness in the Americas: A Decade of SARInet's Impact
Read the supplement
40 years of fighting infectious diseases in Peru and Central and South America, 1984–2023
Read the supplement
Harnessing Real-world Data to Inform Clinical Practice: Lessons From the Evolving COVID-19 Era
Read the supplement
2024 Reviewer of the Year Recipients
The IDSA journals congratulate the 2024 Reviewer of the Year awardees for their excellence in completing peer reviews for IDSA’s three journals. JID's 2024 recipients are Kathryn M. Edwards, MD, FIDSA, Robert L. Atmar, MD, FIDSA, and Michael Ison, MD, MS, FIDSA. Reviewers were selected through IDSA’s reviewer recognition and rewards program.
Author Resources
Interested in publishing with JID?
Read the author guidelines to learn more about the JID submission process, and then submit your paper using our online submission system.
Open Access
Authors interested in publishing in JID may be able to publish their paper open access using funds available through their institution's agreement with OUP.
Publishing Process Support
Whether you are preparing your manuscript for submission, are wondering what to do once your manuscript has been accepted or are trying to find out how to promote your article, we have general resources to help you along the way.How to Write a Publishable Manuscript
Watch Dr. Martin S. Hirsch's presentation on writing successful manuscripts.
IDSA Thanks Retiring JID Editors
As the term of Martin S. Hirsch, MD, FIDSA, as editor-in-chief of The Journal of Infectious Diseases ends, the Infectious Diseases Society of America wishes to thank him and all members of his editorial board for their extraordinary work as journal and Society leaders.
Learn more
IDSA Information
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases.
Learn more
Stay Connected
The IDSA Journals app gives you the freedom to read The Journal of Infectious Diseases both online and offline, on your iPad, iPhone, or iPod Touch.
Register for email alerts and get notified as soon as new issue is published online.
